|
| 36854071 | Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. | J Clin Oncol | 2023 |
| 34623519 | Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma. | J Cancer Res Clin Oncol | 2022 |
| 35859155 | Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup. | Sci Rep | 2022 |
| 36054432 | Human repair-related Schwann cells adopt functions of antigen-presenting cells in vitro. | Glia | 2022 |
| 33316634 | Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience. | Eur J Cancer | 2021 |
| 33627664 | Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. | Nat Commun | 2021 |
| 33712610 | Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8. | Nat Commun | 2021 |
| 33540616 | Long-Term Outcome and Role of Biology within Risk-Adapted Treatment Strategies: The Austrian Neuroblastoma Trial A-NB94. | Cancers (Basel) | 2021 |
| 33784615 | Evaluation of Deep Learning Architectures for Complex Immunofluorescence Nuclear Image Segmentation. | IEEE Trans Med Imaging | 2021 |
| 34815394 | Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. | Nat Commun | 2021 |
| 34503120 | Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging. | Cancers (Basel) | 2021 |
| 34152804 | Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. | J Clin Oncol | 2021 |
| 34115544 | Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). | J Clin Oncol | 2021 |
| 34050156 | Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. | Nat Commun | 2021 |
| 32497717 | Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis. | J Mol Diagn | 2020 |
| 32013055 | Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). | Cancers (Basel) | 2020 |
| 32903140 | Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. | J Clin Oncol | 2020 |
| 32782410 | An annotated fluorescence image dataset for training nuclear segmentation methods. | Sci Data | 2020 |
| 32639845 | Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. | J Clin Oncol | 2020 |
| 30585743 | DeepSNP: An End-to-End Deep Neural Network with Attention-Based Localization for Breakpoint Detection in Single-Nucleotide Polymorphism Array Genomic Data. | J Comput Biol | 2019 |
| 28921546 | Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression. | Int J Cancer | 2018 |
| 30442501 | Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. | Lancet Oncol | 2018 |
| 29755120 | Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. | Br J Cancer | 2018 |
| 29546701 | Detailed Protocols for the Isolation, Culture, Enrichment and Immunostaining of Primary Human Schwann Cells. | Methods Mol Biol | 2018 |
| 29514301 | Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. | J Natl Cancer Inst | 2018 |
| 27984660 | Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. | Cancer | 2017 |
| 28259608 | Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. | Lancet Oncol | 2017 |
| 28228384 | Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone. | Clin Cancer Res | 2017 |
| 28134926 | DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. | Nat Med | 2017 |
| 26119945 | Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. | Oncogene | 2016 |
| 26657295 | Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. | Oncotarget | 2016 |
| 27560999 | Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors. | PLoS One | 2016 |
| 27550150 | Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. | Acta Neuropathol Commun | 2016 |
| 27545331 | Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human Schwann cell repair phenotype. | Glia | 2016 |
| 27432915 | Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. | J Clin Oncol | 2016 |
| 26910568 | The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma. | Int J Cancer | 2016 |
| 26709890 | Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. | Cancer | 2016 |
| 25356804 | Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. | Br J Cancer | 2015 |
| 26360775 | Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies-A Validation Study. | PLoS One | 2015 |
| 26304901 | Advances in Risk Classification and Treatment Strategies for Neuroblastoma. | J Clin Oncol | 2015 |
| 26497213 | Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. | Oncotarget | 2015 |
| 25467309 | Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses. | Mol Oncol | 2015 |
| 24246703 | Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma. | Eur J Cancer | 2014 |
| 25044743 | Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. | Pediatr Blood Cancer | 2014 |
| 25161957 | Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics. | Front Oncol | 2014 |
| 25154816 | Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. | J Clin Oncol | 2014 |
| 24663047 | Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. | J Clin Oncol | 2014 |
| 24038992 | Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. | Pediatr Blood Cancer | 2014 |
| 24303312 | Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. | AMIA Jt Summits Transl Sci Proc | 2013 |
| 22137163 | Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. | Eur J Cancer | 2012 |